Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma by Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng, Lida Wang

Subjects: Get full text

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment by Sonia Morè, Maria Teresa Petrucci, Laura Corvatta, Francesca Fazio, Massimo Offidani, Attilio Olivieri

Subjects: Get full text

Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression by WANG Yuanyuan, ZHA Yong, ZHANG Siyu

Subjects: Get full text

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from th... by Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann, Sandra Sauer

Subjects: Get full text

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone by Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito, Aki Sakurai, Tomonori Nakazato

Subjects: Get full text

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage T... by Fortunato Morabito, Fortunato Morabito, Elena Zamagni, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Michele Cavo, Antonino Neri, Massimo Gentile

Subjects: Get full text

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab by Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA

Subjects: “…elotuzumab…”
Get full text

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms by Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell

Subjects: Get full text

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments by Emily Chu, Jian Wu, Stacey S. Kang, Yubin Kang

Subjects: Get full text

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma by Kerry S. Campbell, Adam D. Cohen, Tatiana Pazina, Tatiana Pazina

Subjects: Get full text

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma by Friend R, Bhutani M, Voorhees PM, Usmani SZ

Subjects: Get full text

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines by Lawrence G. Lum, Archana Thakur, Abdalla Elhakiem, Lena Alameer, Emily Dinning, Manley Huang

Subjects: Get full text

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE by Morgane Humbel, Florence Bellanger, Natalia Fluder, Alice Horisberger, Madeleine Suffiotti, Craig Fenwick, Camillo Ribi, Denis Comte

Subjects: Get full text

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department by Yu. E. Ryabukhina, P. A. Zeynalova, F. M. Abbasbeyli, O. L. Timofeeva, N. A. Kupryshina, T. T. Valiev

Subjects: Get full text

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma by S. V. Semochkin

Subjects: Get full text

ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING by Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

Subjects: “…Elotuzumab…”
Get full text

Elotuzumab as a novel anti-myeloma immunotherapy by Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Steinbach, Janet Weidner, Tim Luetkens, Djordje Atanackovic

Subjects: Get full text

SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy by Pooya Farhangnia, Pooya Farhangnia, Pooya Farhangnia, Shamim Mollazadeh Ghomi, Shabnam Mollazadehghomi, Hamid Nickho, Hamid Nickho, Mahzad Akbarpour, Mahzad Akbarpour, Ali-Akbar Delbandi, Ali-Akbar Delbandi

Subjects: Get full text

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a... by Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, Hartmut Goldschmidt

Subjects: Get full text